drugset / Trial / NCT03919656
SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
Phase 4
Completed
60 enrolled
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
RandomizedParallel-groupDouble-blindBasic science
Summary
This study evaluates the metabolomics changes associated with dapagliflozin treatment in patients with type 2 diabetes mellitus (T2DM). The participants in the study will be randomized to receive 10 mg dapagliflozin or placebo once daily for 12 weeks.
Timeline
- Start
- 2019-05-12
- Primary completion
- 2024-01-12
- Completion
- 2024-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |